Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NITROLINGUAL PUMPSPRAY vs IMDUR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Nitroglycerin is converted to nitric oxide (NO) in vascular smooth muscle, activating guanylate cyclase and increasing cyclic guanosine monophosphate (c GMP), leading to vasodilation of peripheral arteries and veins. This reduces preload and afterload, decreasing myocardial oxygen demand.
Isosorbide mononitrate is a nitrate vasodilator that relaxes vascular smooth muscle via conversion to nitric oxide (NO), which activates guanylate cyclase, increasing c GMP levels, leading to vasodilation. It primarily dilates veins (venodilation) with lesser effects on arteries, reducing preload and afterload, thereby decreasing myocardial oxygen demand.
Treatment of acute angina pectoris,Prophylaxis of angina pectoris (prior to activities that may provoke an attack)
Prevention of angina pectoris due to coronary artery disease,Off-label: chronic heart failure (as adjunctive therapy), esophageal spasm
1-2 sprays sublingually at onset of angina; may repeat every 5 minutes up to 3 doses in 15 minutes. Prophylaxis: 1 spray 5-10 minutes before activity.
Initial: 30-60 mg orally once daily; titrate to 120 mg once daily as tolerated. Maximum: 240 mg once daily.
Terminal elimination half-life of nitroglycerin is 1–4 minutes; however, clinical hemodynamic effects last longer due to active metabolites and tissue distribution.
Terminal elimination half-life of isosorbide mononitrate is approximately 5 hours. This supports once-daily dosing for IMDUR (extended-release formulation) due to prolonged absorption phase.
Metabolized primarily in the liver by the enzyme glutathione nitrate reductase, and also by red blood cells and vascular smooth muscle. Metabolites include 1,2-glyceryl dinitrate and 1,3-glyceryl dinitrate, which have minimal vasodilatory activity.
Primarily hepatic metabolism via denitration and glucuronidation; isosorbide mononitrate is the active metabolite of isosorbide dinitrate and does not undergo significant first-pass metabolism.
Renal excretion of inactive metabolites (nitrate ions) accounts for approximately 80% of elimination; biliary/fecal excretion is minimal (less than 5%).
Isosorbide dinitrate (IMDUR active metabolite? Actually IMDUR is isosorbide mononitrate, the active metabolite of isosorbide dinitrate. For isosorbide mononitrate: renal excretion is approximately 96% as metabolites, with about 2% unchanged; biliary/fecal excretion is minimal, <2%.
Approximately 60% bound, primarily to albumin.
Less than 5%, primarily to albumin. Very low protein binding, which contributes to high free fraction.
3.3 L/kg, indicating extensive extravascular distribution.
Volume of distribution is approximately 0.6-0.7 L/kg for isosorbide mononitrate. This moderate Vd indicates distribution into total body water and some tissue binding.
Sublingual spray: approximately 40% (due to first-pass metabolism in liver and gastrointestinal tissues after swallowing).
Oral bioavailability is nearly 100% for isosorbide mononitrate due to lack of first-pass metabolism (unlike isosorbide dinitrate). For IMDUR extended-release, relative bioavailability is comparable to immediate-release, with controlled release properties.
No dose adjustment required for any degree of renal impairment.
No dosage adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min, use with caution; consider starting at 30 mg once daily and titrate slowly.
Dose reduction may be needed in severe hepatic impairment (Child-Pugh C); start with lowest effective dose.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose by 50%; start at 30 mg once daily. Child-Pugh Class C: Contraindicated or use with extreme caution; start at 30 mg once daily with careful monitoring.
Safety and efficacy not established; not recommended for use in pediatric patients.
Not approved for pediatric use. Limited data: 0.5-2 mg/kg orally once daily, not to exceed 120 mg once daily.
Initiate with lowest effective dose; increased sensitivity to hypotension due to age-related changes in baroreceptor reflexes.
Start at 30 mg once daily; titrate slowly due to increased sensitivity and risk of hypotension.
Coadministration with phosphodiesterase-5 (PDE5) inhibitors (e.g., sildenafil, tadalafil, vardenafil) is contraindicated due to the risk of severe hypotension, syncope, and myocardial ischemia.
Not recommended for use in patients with acute myocardial infarction (MI) or congestive heart failure (CHF) requiring rapid hemodynamic monitoring; use only under close clinical observation.
Hypotension: May cause severe hypotension in patients with hypovolemia or low systolic blood pressure.,Hepatic impairment: Use with caution in patients with severe hepatic disease.,Headache: Common and may be severe; tolerance may develop.,Sublingual administration: Do not inhale; spray onto or under the tongue.,Overuse: Excessive use may result in tolerance and reduced efficacy.
Hypotension: may cause severe hypotension, especially with upright posture,Tolerance: continuous use may lead to tolerance and cross-tolerance to other nitrates; use with a daily nitrate-free interval,Headache: often occurs but may diminish with continued use,Glaucoma: controversial; generally considered safe,Volume depletion: increased risk of hypotension
Hypersensitivity to nitroglycerin or any component of the formulation,Concurrent use with phosphodiesterase-5 (PDE5) inhibitors (e.g., sildenafil, tadalafil, vardenafil),Severe anemia,Increased intracranial pressure (e.g., head trauma, cerebral hemorrhage),Constrictive pericarditis or cardiac tamponade
Hypersensitivity to isosorbide mononitrate or other nitrates,Concurrent use with phosphodiesterase-5 inhibitors (e.g., sildenafil, tadalafil, vardenafil) due to risk of severe hypotension,Severe anemia,Increased intracranial pressure (e.g., head trauma, cerebral hemorrhage),Acute circulatory failure or shock
Avoid alcohol consumption as it may increase hypotensive effects. No specific food interactions; consult healthcare provider regarding dietary concerns.
Avoid high-fat meals as they may delay absorption. No specific food interactions; alcohol may increase hypotensive effects.
Nitroglycerin (NTG) is classified as FDA Pregnancy Category C. Animal reproduction studies are inadequate. In first trimester, limited human data show no consistent association with major malformations. During second and third trimesters, use is reserved for acute hypertensive crises or pulmonary edema; potential risks include maternal hypotension leading to uteroplacental hypoperfusion and fetal hypoxia. Avoid near term due to risk of maternal hypotension and possible fetal distress.
FDA Pregnancy Category C. In animal studies, isosorbide mononitrate (IMDUR) caused embryotoxicity and fetotoxicity at high doses. There are no adequate and well-controlled studies in pregnant women. Use only if potential benefit justifies potential risk to the fetus. First trimester: No specific malformation pattern identified. Second and third trimesters: Potential risk of fetal hypotension and reduced placental perfusion due to maternal vasodilation.
No human data on NTG excretion in breast milk. M/P ratio is unknown. Based on molecular weight (227.09 Da) and short half-life (1-3 min), transfer is likely minimal. Use with caution in breastfeeding only if clearly needed; monitor infant for hypotension or methemoglobinemia (rare).
Unknown if isosorbide mononitrate is excreted in human breast milk. M/P ratio not established. Caution advised; consider discontinuing nursing or drug, balancing importance of drug to mother.
No systematic pharmacokinetic studies in pregnancy. Physiological changes (increased plasma volume, renal clearance) may alter distribution. No dose adjustment recommendations exist; use lowest effective dose. Initial dose: 1-2 sprays (0.4-0.8 mg) sublingually, repeat every 5 minutes up to 3 doses. Monitor for exaggerated hypotension due to decreased vascular resistance in pregnancy.
No specific dose adjustments recommended for pregnancy; however, hemodynamic changes (increased plasma volume, cardiac output) may alter pharmacokinetics. Start at lowest effective dose and titrate based on maternal response and tolerability.
Nitrolingual Pumpspray (nitroglycerin) is a sublingual spray for acute angina. Onset of action is 1-3 minutes. Do not shake before use. Prime pump with 5 sprays if new or not used for 6 weeks. Avoid concurrent use of PDE5 inhibitors (e.g., sildenafil) due to severe hypotension. Monitor for hypotension, syncope, and headache. Tolerance develops with frequent use; provide nitrate-free interval.
Imdur (isosorbide mononitrate) is an extended-release nitrate used for angina prophylaxis. Avoid concomitant use with phosphodiesterase-5 inhibitors (e.g., sildenafil) due to risk of severe hypotension. Tachyphylaxis can occur with continuous use; maintain a daily nitrate-free interval (typically 10-12 hours) to preserve efficacy. Do not crush or chew extended-release tablets. Monitor blood pressure and heart rate during initiation. Use with caution in patients with hypertrophic obstructive cardiomyopathy, aortic stenosis, or volume depletion.
Use 1-2 sprays at the first sign of angina, under the tongue, not inhaled.,Do not shake the bottle before use.,Prime the pump with 5 sprays if new or not used for 6 weeks.,Sit down when using to avoid fainting from low blood pressure.,Seek emergency if pain not relieved after 3 doses (5 minutes apart).,Avoid alcohol and erectile dysfunction drugs (e.g., sildenafil, tadalafil).
Take Imdur exactly as prescribed, usually once daily in the morning to maintain a nitrate-free interval.,Do not crush, chew, or cut the tablet; swallow it whole with a glass of water.,Avoid taking erectile dysfunction medications (e.g., Viagra, Cialis, Levitra) while on Imdur, as this can cause a dangerous drop in blood pressure.,If you experience headache, it may indicate the drug is working; acetaminophen can help. Inform your doctor if headaches persist.,Store at room temperature, away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NITROLINGUAL PUMPSPRAY vs IMDUR, answered by our medical review team.
NITROLINGUAL PUMPSPRAY is a Nitrate Vasodilator that works by Nitroglycerin is converted to nitric oxide (NO) in vascular smooth muscle, activating guanylate cyclase and increasing cyclic guanosine monophosphate (c GMP), leading to vasodilation of peripheral arteries and veins. This reduces preload and afterload, decreasing myocardial oxygen demand.. IMDUR is a Nitrate Vasodilator that works by Isosorbide mononitrate is a nitrate vasodilator that relaxes vascular smooth muscle via conversion to nitric oxide (NO), which activates guanylate cyclase, increasing c GMP levels, leading to vasodilation. It primarily dilates veins (venodilation) with lesser effects on arteries, reducing preload and afterload, thereby decreasing myocardial oxygen demand.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NITROLINGUAL PUMPSPRAY and IMDUR depend on the specific clinical indication. These are both Nitrate Vasodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NITROLINGUAL PUMPSPRAY is: 1-2 sprays sublingually at onset of angina; may repeat every 5 minutes up to 3 doses in 15 minutes. Prophylaxis: 1 spray 5-10 minutes before activity.. The standard adult dose of IMDUR is: Initial: 30-60 mg orally once daily; titrate to 120 mg once daily as tolerated. Maximum: 240 mg once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NITROLINGUAL PUMPSPRAY and IMDUR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NITROLINGUAL PUMPSPRAY is classified as Category C. Nitroglycerin (NTG) is classified as FDA Pregnancy Category C. Animal reproduction studies are inadequate. In first trimester, limited human data show no consistent association wit. IMDUR is classified as Category C. FDA Pregnancy Category C. In animal studies, isosorbide mononitrate (IMDUR) caused embryotoxicity and fetotoxicity at high doses. There are no adequate and well-controlled studies . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.